Cellebrite DI Ltd. (CLBT) Key Metrics
CLBT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.77B
- Enterprise value
- $2.47B
- P/E (TTM)
- 48.0 10-yr median 37.8
- Forward P/E
- 35.7
- PEG ratio
- —
- Price / sales
- 5.4 10-yr median 7.4
- Price / book
- 5.4 10-yr median 13.7
- EV / EBITDA
- 24.0 10-yr median 26.1
- Dividend yield
- —
- Beta
- 1.13
CLBT key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCLBT valuation Price multiples at each fiscal year-end price.
CLBT returns How much profit the business earns on the capital it uses.
CLBT per-share figures Results divided by the shares outstanding at year-end.
CLBT financial health Debt, liquidity and how easily interest is covered.
CLBT efficiency & capital use Working capital cycle and where the cash goes.
CLBT valuation history
CLBT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CLBT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CLBT cash returned to shareholders
CLBT price vs earnings per share
CLBT key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $4.51B | $4.61B | $1.65B | $851.9M | $1.30B | $1.97B | — |
| Enterprise value | $4.09B | $4.18B | $1.36B | $683.6M | $1.11B | $1.73B | — |
| P/E ratio | 57.5 | — | — | 7.1 | 18.1 | 340.9 | — |
| Price / sales | 9.5 | 11.5 | 5.1 | 3.1 | 5.3 | 10.1 | — |
| Price / book | 9.3 | 13.7 | 48.1 | 11.5 | — | 30.9 | — |
| Price / free cash flow | 28.9 | 38.0 | 17.5 | 74.1 | 46.4 | 32.7 | — |
| Price / operating cash flow | 26.7 | 34.9 | 16.1 | 41.4 | 35.9 | 29.6 | — |
| EV / sales | 8.6 | 10.4 | 4.2 | 2.5 | 4.5 | 8.9 | — |
| EV / EBITDA | 39.7 | — | — | 5.3 | 12.5 | 100.3 | — |
| EV / free cash flow | 26.3 | 34.4 | 14.4 | 59.5 | 39.9 | 28.7 | — |
| Earnings yield | 1.7% | −6.1% | −4.9% | 14.2% | 5.5% | 0.3% | — |
| Free cash flow yield | 3.5% | 2.6% | 5.7% | 1.3% | 2.2% | 3.1% | — |
| Dividend yield | — | — | 0.0% | 0.0% | 7.7% | 0.5% | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | 0.0% | 0.0% | 7.7% | 0.5% | — |
| Share price at fiscal year-end | $18.03 | $22.03 | $8.66 | $4.36 | $8.02 | $10.53 | — |
| Per share | |||||||
| Revenue per share | $1.90 | $1.92 | $1.71 | $1.39 | $1.52 | $1.04 | $0.92 |
| Earnings per share | $0.31 | −$1.35 | −$0.43 | $0.62 | $0.44 | $0.03 | −$0.01 |
| Operating cash flow per share | $0.68 | $0.63 | $0.54 | $0.11 | $0.22 | $0.36 | $0.09 |
| Free cash flow per share | $0.62 | $0.58 | $0.50 | $0.06 | $0.17 | $0.32 | $0.05 |
| Cash per share | $1.75 | $2.14 | $1.59 | $0.94 | $1.12 | $1.27 | $1.07 |
| Book value per share | $1.94 | $1.60 | $0.18 | $0.38 | −$0.45 | $0.34 | $0.31 |
| Tangible book value per share | $1.13 | $1.41 | −$0.02 | $0.18 | −$0.69 | $0.26 | $0.31 |
| Dividends per share | — | — | $0.00 | $0.00 | $0.62 | $0.05 | $0.13 |
| Capex per share | $0.05 | $0.05 | $0.04 | $0.05 | $0.05 | $0.03 | $0.03 |
| Debt per share | $0.09 | $0.05 | $0.07 | $0.08 | — | — | — |
| Shares outstanding | 249.9M | 209.5M | 190.2M | 195.4M | 161.5M | 187.2M | 187.2M |
| Change in shares outstanding | +19.3% | +10.2% | −2.7% | +21.0% | −13.7% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | 19.1% | −152.9% | −150.1% | — | — | 9.4% | −3.2% |
| Return on assets (ROA) | 9.6% | −46.3% | −17.3% | 32.5% | 20.3% | 1.8% | −0.7% |
| Return on tangible assets | 10.6% | −43.5% | −16.4% | 33.1% | 23.7% | 1.7% | −0.7% |
| Free cash flow margin | 32.7% | 30.3% | 29.0% | 4.2% | 11.3% | 31.0% | 5.8% |
| Income quality (OCF / net income) | 2.16 | — | — | 0.17 | 0.50 | 11.50 | — |
| Financial health | |||||||
| Total debt | $22.7M | $11.0M | $14.1M | $15.4M | — | — | — |
| Cash & short-term investments | $437.1M | $447.2M | $302.9M | $183.6M | $181.6M | $237.6M | $200.3M |
| Net debt | −$414.4M | −$436.3M | −$288.8M | −$168.3M | −$181.6M | −$237.6M | −$200.3M |
| Debt / equity | 0.05 | 0.03 | 0.41 | 0.21 | — | — | — |
| Debt / assets | 0.02 | 0.02 | 0.03 | 0.04 | — | — | — |
| Net debt / EBITDA | −4.02 | — | — | −1.29 | −2.03 | −13.76 | −35.61 |
| Current ratio | 1.56 | 1.92 | 1.66 | 1.42 | 1.46 | 2.03 | 2.64 |
| Quick ratio | 1.54 | 1.89 | 1.62 | 1.38 | 1.43 | 2.00 | 2.60 |
| Interest coverage | 127.1 | 0.2 | 235.7 | 7.0 | 90.3 | 6.5 | -4.3 |
| Working capital | $206.2M | $272.1M | $168.3M | $88.2M | $86.6M | $164.9M | $162.7M |
| Invested capital | $69.9M | −$100.2M | −$254.6M | −$94.4M | −$254.9M | −$173.8M | −$141.4M |
| Tangible asset value | $283.3M | $296.0M | −$3.2M | $35.8M | −$111.4M | $47.7M | $58.8M |
| Net current asset value | $121.3M | $213.0M | −$76.6M | −$33.5M | −$139.9M | $23.7M | $40.5M |
| Graham number | $3.70 | — | — | $2.29 | — | $0.49 | — |
| Graham net-net per share | $0.26 | $0.76 | −$0.70 | −$0.42 | −$1.10 | −$0.06 | $0.07 |
| Capital allocation | |||||||
| Dividends paid | — | — | $0 | $0 | $100.0M | $10.0M | $25.0M |
| Share buybacks (net) | — | $11,000 | — | $0 | $0 | $85,000 | $808,000 |
| Dividend payout ratio | — | — | — | 0.0% | 140.1% | 173.0% | — |
| Dividends + buybacks / free cash flow | — | 0.0% | 0.0% | 0.0% | 357.9% | 16.7% | 260.1% |
| Capex / revenue | 2.8% | 2.6% | 2.4% | 3.4% | 3.3% | 3.2% | 3.6% |
| Capex / operating cash flow | 7.8% | 8.0% | 7.8% | 44.2% | 22.5% | 9.3% | 38.5% |
| Capex / depreciation | 1.11 | 1.00 | 0.79 | 0.99 | 1.14 | 1.05 | 1.52 |
| Stock-based compensation / revenue | 9.4% | 7.6% | 5.8% | 5.1% | 2.6% | 3.7% | 7.4% |
| R&D / revenue | 23.9% | 24.5% | 26.0% | 29.8% | 26.6% | 27.9% | 27.1% |
| SG&A / revenue | 46.3% | 45.7% | 47.4% | 51.1% | 50.5% | 46.8% | 52.5% |
| Efficiency | |||||||
| Days sales outstanding | 71.9 | 72.6 | 87.6 | 98.6 | 99.2 | 103.5 | 94.0 |
| Days of inventory on hand | 40.2 | 55.0 | 69.0 | 60.0 | 48.3 | 42.0 | 40.3 |
| Days payables outstanding | 67.8 | 56.4 | 44.2 | 50.9 | 61.2 | 48.6 | 54.6 |
| Cash conversion cycle (days) | 44.3 | 71.2 | 112.3 | 107.7 | 86.3 | 96.9 | 79.7 |
| Receivables turnover | 5.08 | 5.03 | 4.17 | 3.70 | 3.68 | 3.53 | 3.88 |
| Payables turnover | 5.39 | 6.47 | 8.26 | 7.17 | 5.96 | 7.51 | 6.68 |
| Inventory turnover | 9.09 | 6.63 | 5.29 | 6.08 | 7.56 | 8.69 | 9.05 |
| Asset turnover | 0.58 | 0.66 | 0.69 | 0.73 | 0.70 | 0.60 | 0.61 |
| Average receivables | $93.7M | $79.8M | $78.0M | $73.1M | $66.9M | $55.3M | $44.2M |
| Average payables | $14.0M | $9.7M | $6.4M | $7.1M | $7.1M | $5.0M | $5.4M |
| Average inventory | $8.3M | $9.4M | $10.1M | $8.3M | $5.6M | $4.4M | $4.0M |
| Intangibles / total assets | 21.4% | 5.8% | 7.0% | 9.4% | 11.2% | 4.4% | 0.0% |
Computed from CLBT's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CLBT valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Cellebrite DI traded at 57.5 times earnings, against a 7-year median of 37.8. Based on the latest twelve months, the trailing P/E is 48.0 and the forward P/E is 35.7. Cellebrite DI earned a return on equity of 19.1% in fiscal 2025. It ended the year with $22.7 million of debt and $437.1 million in cash and short-term investments, a net cash position of $414.4 million. The share count rose 33.5% from 187.2M to 249.9M over 6 years.
See the CLBT income statement, the CLBT chart for price history, or the CLBT stock overview for the latest quote and news.
CLBT key metrics FAQ
What is Cellebrite DI's P/E ratio?
Cellebrite DI's trailing P/E ratio is 48.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 35.7. At the end of fiscal 2025 it was 57.5, compared with a 7-year median of 37.8.
What is Cellebrite DI's EV/EBITDA?
Cellebrite DI's enterprise value was 39.7 times EBITDA at the end of fiscal 2025 (enterprise value $4.1 billion, EBITDA $103.1 million); the current EV/EBITDA is 24.0.
What is Cellebrite DI's return on equity?
Cellebrite DI's return on equity (ROE) was 19.1% in fiscal 2025: net income of $78.3 million on average shareholders' equity of $410.2 million.
How much debt does Cellebrite DI have?
Cellebrite DI had total debt of $22.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Cellebrite DI's free cash flow yield?
Cellebrite DI generated $155.7 million of free cash flow in fiscal 2025, a free cash flow yield of 3.5% on its market value at year-end ($4.5 billion).
What is Cellebrite DI's current ratio?
Cellebrite DI's current ratio was 1.56 at the end of fiscal 2025: current assets were 1.56 times current liabilities.